QURE Collar Strategy
QURE (uniQure N.V.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
QURE (uniQure N.V.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.82B, a beta of 0.87 versus the broader market, a 52-week range of 8.73-71.5, average daily share volume of 3.4M, a public-listing history dating back to 2014, approximately 209 full-time employees. These structural characteristics shape how QURE stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.87 places QURE roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a collar on QURE?
A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot.
Current QURE snapshot
As of May 15, 2026, spot at $26.65, ATM IV 120.60%, IV rank 28.12%, expected move 34.57%. The collar on QURE below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this collar structure on QURE specifically: IV regime affects collar pricing on both sides; compressed QURE IV at 120.60% typically pushes the short call premium to roughly offset the long put cost, with a market-implied 1-standard-deviation move of approximately 34.57% (roughly $9.21 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated QURE expiries trade a higher absolute premium for lower per-day decay. Position sizing on QURE should anchor to the underlying notional of $26.65 per share and to the trader's directional view on QURE stock.
QURE collar setup
The QURE collar below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With QURE near $26.65, the first option leg uses a $28.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed QURE chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 QURE shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $26.65 | long |
| Sell 1 | Call | $28.00 | $3.55 |
| Buy 1 | Put | $25.00 | $2.88 |
QURE collar risk and reward
- Net Premium / Debit
- -$2,597.50
- Max Profit (per contract)
- $202.50
- Max Loss (per contract)
- -$97.50
- Breakeven(s)
- $25.97
- Risk / Reward Ratio
- 2.077
Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium.
QURE collar payoff curve
Modeled P&L at expiration across a range of underlying prices for the collar on QURE. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$97.50 |
| $5.90 | -77.9% | -$97.50 |
| $11.79 | -55.7% | -$97.50 |
| $17.68 | -33.6% | -$97.50 |
| $23.58 | -11.5% | -$97.50 |
| $29.47 | +10.6% | +$202.50 |
| $35.36 | +32.7% | +$202.50 |
| $41.25 | +54.8% | +$202.50 |
| $47.14 | +76.9% | +$202.50 |
| $53.03 | +99.0% | +$202.50 |
When traders use collar on QURE
Collars on QURE hedge an existing long QURE stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
QURE thesis for this collar
The market-implied 1-standard-deviation range for QURE extends from approximately $17.44 on the downside to $35.86 on the upside. A QURE collar hedges an existing long QURE position with a protective put while financing the put cost via a short call; when the premiums roughly offset, the collar acts as a near-zero-cost insurance band around the current spot. Current QURE IV rank near 28.12% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on QURE at 120.60%. As a Healthcare name, QURE options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to QURE-specific events.
QURE collar positions are structurally neutral (protective); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. QURE positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move QURE alongside the broader basket even when QURE-specific fundamentals are unchanged. Always rebuild the position from current QURE chain quotes before placing a trade.
Frequently asked questions
- What is a collar on QURE?
- A collar on QURE is the collar strategy applied to QURE (stock). The strategy is structurally neutral (protective): A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot. With QURE stock trading near $26.65, the strikes shown on this page are snapped to the nearest listed QURE chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are QURE collar max profit and max loss calculated?
- Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium. For the QURE collar priced from the end-of-day chain at a 30-day expiry (ATM IV 120.60%), the computed maximum profit is $202.50 per contract and the computed maximum loss is -$97.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a QURE collar?
- The breakeven for the QURE collar priced on this page is roughly $25.97 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current QURE market-implied 1-standard-deviation expected move is approximately 34.57%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a collar on QURE?
- Collars on QURE hedge an existing long QURE stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
- How does current QURE implied volatility affect this collar?
- QURE ATM IV is at 120.60% with IV rank near 28.12%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.